Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2013 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Non-Current Deffered Revenue of $136.4 million for Q1 2026, down 58.04% year-over-year from $325.0 million in Q1 2025, and up 62.5% quarter-over-quarter from $83.9 million in Q4 2025.
Sarepta Therapeutics (SRPT) Non-Current Deffered Revenue (2013 - 2026) Analysis & Trends
Sarepta Therapeutics' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $136.4 million for Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue fell 58.04% year-over-year to $136.4 million; the TTM figure through Mar 2026 stood at $136.4 million (down 58.04% YoY), while the FY2025 annual figure was $83.9 million, down 74.18% from the prior year.
- Non-Current Deffered Revenue for Q1 2026 stood at $136.4 million, up from $83.9 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $552.2 million in Q1 2022, with the low at $83.9 million in Q4 2025.
- The 5-year median for Non-Current Deffered Revenue is $437.0 million (2023), against an average of $387.5 million.
- Peak annual rise in Non-Current Deffered Revenue reached 0.0% in 2025, while the deepest fall reached 74.18% in 2025.
- Sarepta Therapeutics' Non-Current Deffered Revenue stood at $485.0 million in 2022, then declined by 9.9% to $437.0 million in 2023, then slipped by 25.63% to $325.0 million in 2024, then slumped by 74.18% to $83.9 million in 2025, then surged by 62.5% to $136.4 million in 2026.
- Business Quant data shows SRPT's Non-Current Deffered Revenue at $136.4 million in Q1 2026, $83.9 million in Q4 2025, and $325.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 110.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.13 Mn |
| Mar 31, 2026 | 136.35 Mn |
| Dec 31, 2025 | 83.91 Mn |
| Mar 31, 2025 | 325.00 Mn |
| Dec 31, 2024 | 325.00 Mn |
| Sep 30, 2024 | 325.00 Mn |
| Jun 30, 2024 | 325.00 Mn |
| Mar 31, 2024 | 325.00 Mn |
| Dec 31, 2023 | 437.00 Mn |
| Sep 30, 2023 | 485.00 Mn |
| Jun 30, 2023 | 485.00 Mn |
| Mar 31, 2023 | 485.00 Mn |
| Dec 31, 2022 | 485.00 Mn |
| Sep 30, 2022 | 507.49 Mn |
| Jun 30, 2022 | 529.99 Mn |
| Mar 31, 2022 | 552.24 Mn |
| Dec 31, 2021 | 574.24 Mn |
| Sep 30, 2021 | 596.74 Mn |
| Jun 30, 2021 | 619.23 Mn |
| Mar 31, 2021 | 641.48 Mn |